GLP-1 medication

A Reuters newsletter reports that GLP-1 drugs help control prediabetes better than the current standard medicine. The finding adds to growing evidence that the class of drugs, already widely used for diabetes and weight loss, may benefit people with elevated blood sugar before full diabetes develops. The news is drawing attention from patients and clinicians watching the rapidly expanding GLP-1 market.

Meal delivery company Fuel Meals has introduced specialized GLP-1 meal plans designed around protein-first nutrition and the reduced appetite common among people taking medications like Ozempic and Wegovy. The plans aim to help users meet protein needs and manage smaller appetites while on GLP-1 treatments, a fast-growing category of weight-loss drugs.

MultiCare, a Washington-based health system, has published an explainer in its Vitals series covering GLP-1 medications, the class of drugs that includes semaglutide and tirzepatide, widely prescribed for type 2 diabetes and weight loss. The guide explains how the drugs work, who may qualify, and what patients should know before starting treatment.

Blood sugar control is dominating Italian health news. A lab-made probiotic that produces GLP-1 and lowers glucose has been announced, while a Zurich implant reportedly burns blood sugar without medication. Other reports link medical stress to glucose spikes and stress the role of diet alongside GLP-1 drugs, as EU health officials push cardiovascular screening and prevention across member states.

UConn Health is drawing attention to its research aimed at improving GLP-1 medications, the class of drugs widely used for diabetes and weight loss. The university is sharing the work through its short 'Health Minute' news segments, which highlight medical research for a general audience. The item comes as GLP-1 drugs remain one of the most talked-about topics in healthcare.

Food Business News explores how nutrition can support people taking GLP-1 medications, the class of drugs increasingly used for weight loss and diabetes management. The piece highlights the importance of adequate protein, fibre and micronutrient intake for patients whose reduced appetite can limit how much they eat.

Food industry distributor Univar Solutions is discussing how GLP-1 weight-loss drugs, affordability pressures and evolving nutrition demands are shaping the food ingredients market. The company's comments highlight how manufacturers are adapting formulations as consumers on appetite-suppressing medications seek nutrient-dense, affordable products.

Doctors report heavier workloads as growing numbers of patients take GLP-1 medications like Ozempic and Wegovy. Clinicians must manage dosing adjustments, side effects, monitoring and follow-up appointments for these weight-loss and diabetes drugs, adding to already strained schedules. The surge in prescriptions is prompting debate about capacity, staffing and how primary care will cope with sustained demand.

A blended drink of oats, water and lemon, nicknamed 'Oatzempic', is being promoted on social media as a weight-loss aid, with users claiming it keeps them full and helps them shed pounds. Health experts, including Cleveland Clinic dietitians, caution that the drink is not a substitute for GLP-1 medications like Ozempic and that no evidence supports dramatic weight-loss claims.

At the SupplySide Global industry event, panelists outlined opportunities for nutrition and supplement companies to develop products for people taking GLP-1 weight-loss medications such as semaglutide. Discussion focused on how reduced appetite and nutrient intake among users creates demand for protein, micronutrient and muscle-preservation products tailored to this growing consumer group.

A Cleveland Clinic study finds that bariatric surgery remains effective for achieving substantial weight loss in patients who stopped GLP-1 medications due to intolerance or who lost little weight on the drugs. The findings suggest surgery can be a viable next step as use of weight-loss injections like Ozempic and Wegovy continues to expand, informing how doctors sequence obesity treatments.

Australia has approved a GLP-1 medication, previously used mainly to treat diabetes, for weight management and cardiovascular concerns. The regulator's decision makes the drug available as a weight loss option, and coverage is focused on what the approval means for patients seeking treatment and how the medication can now be prescribed and used in Australia.

Actress Chrissy Metz, known for her role in 'This Is Us', has spoken candidly about her experience with GLP-1 medication, discussing what she describes as unexpected upsides of the treatment. She has long been open about her weight and health journey, so her comments on the widely used weight-loss drugs are drawing attention from fans and entertainment media.

GLP-1 drugs appear to control prediabetes better than the current standard medicine, according to a new report circulating in health news. The findings suggest the popular weight-loss and diabetes medications may offer an earlier intervention option for people with elevated blood sugar. Readers and health commentators are weighing what this could mean for future prediabetes treatment guidelines.

LLENA(AI) has announced the launch of a GLP-1 companion program designed to help users on weight-loss medications analyze their meals and build lasting nutrition habits. The program also offers access to major grocery vendors, aiming to support users in maintaining healthy eating alongside their treatment.

Grocery retailers are being urged to plan for customers coming off GLP-1 weight-loss drugs, whose smaller appetites and changed eating habits could reshape food demand. Industry commentary argues stores that adapt with protein-rich foods, smaller portions and health-focused offerings can retain these shoppers long-term as millions cycle on and off the medications.

New findings suggest that about half of people who drink alcohol while taking GLP-1 medications report drinking less since starting the drugs. The observation adds to growing interest in whether popular weight-loss and diabetes drugs like Ozempic and Wegovy may reduce alcohol cravings, with potential implications for treating problem drinking.

New findings reported by the American Heart Association indicate that GLP-1 medications are linked to lower risks of developing type 2 diabetes and cardiovascular problems compared with metformin, the standard medication for diabetes prevention. The news is drawing attention from clinicians and patients weighing GLP-1 drugs for prevention rather than treatment.

A new episode of Science Friday, hosted by Ira Flatow with Flora Lichtman, takes up the practice of microdosing GLP-1 medications such as Ozempic for weight loss, asking whether taking smaller-than-prescribed doses is safe. The segment weighs the appeal of cutting costs and side effects against the lack of clinical evidence for microdosing, as off-label use of these drugs keeps growing.

Ingredients firm IFF has published a new report identifying 10 distinct eating moments tied to GLP-1 weight-loss medication users, aimed at helping food and beverage brands adapt their products and marketing. The analysis outlines how appetite changes on these drugs create new occasions and needs, from smaller portions to nutrient-dense snacking, as the industry responds to shifting consumer behaviour.